Acumen Pharmaceuticals, Inc. Common Stock
ABOS US00509G2093
💰
Capitalization
Small-cap
Acumen Pharmaceuticals Inc is a clinical-stage biopharmaceutical company developing a novel disease-modifying approach to target what it believes to be a key underlying cause of Alzheimer's disease. The company's drug candidate, ACU193, is a subclass monoclonal antibody that selectively targets amyloid-beta oligomers.
🔗
Website
Annual Performance 1
| 2021 | 2022 | 2023 | 2024 | 2025 |
|---|---|---|---|---|
| -66% | -20% | -27% | -59% | 0% |
Annual Insiders Turnover, USD 2
1 annual and historical performance metrics are recalculated on a daily basis;
2 represents the total value of insider transactions (both buying and selling);
Insider Activity
📊
Transactions
16
🙍
Insiders
5
| Person | Price | Shares | Total | Published | Completed |
|---|---|---|---|---|---|
| Zuga Matt CFO |
1.72 USD |
28,902 Sold |
49,633 USD |
21/01/2025 | 23/01/2025 |
| Siemers Eric CMO |
1.59 USD |
3,219 Sold |
5,118 USD |
21/01/2025 | 21/01/2025 |
| Barton Russell COO |
1.61 USD |
2,914 Sold |
4,692 USD |
21/01/2025 | 21/01/2025 |
| Meisner Derek M SR OFF |
1.59 USD |
3,418 Sold |
5,435 USD |
21/01/2025 | 21/01/2025 |
| Oconnell Daniel Joseph CEO |
1.59 USD |
12,619 Sold |
20,102 USD |
21/01/2025 | 21/01/2025 |
| Zuga Matt CFO |
1.60 USD |
4,364 Sold |
6,986 USD |
21/01/2025 | 21/01/2025 |
| Siemers Eric CMO |
1.85 USD |
10,859 Sold |
20,047 USD |
03/01/2025 | 03/01/2025 |
| Zuga Matt CFO |
1.84 USD |
13,235 Sold |
24,367 USD |
03/01/2025 | 03/01/2025 |
| Barton Russell COO |
1.86 USD |
7,636 Sold |
14,225 USD |
03/01/2025 | 03/01/2025 |
| Meisner Derek M SR OFF |
1.84 USD |
11,122 Sold |
20,506 USD |
03/01/2025 | 03/01/2025 |